Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States. The vaccine is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. Dengvaxia is safe and effective in reducing dengue-related hospitalizations and severe dengue among persons who have had dengue infection in the past. Previous natural infection is important because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination. De...
Source: MMWR Recomm Rep - January 3, 2022 Category: Epidemiology Authors: Gabriela Paz-Bailey Laura Adams Joshua M Wong Katherine A Poehling Wilbur H Chen Veronica McNally Robert L Atmar Stephen H Waterman Source Type: research
